Q-omics provides the consensus-scored SPATA21 profile across patient tissues and cancer cell-line models. SPATA21 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SPATA21 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, SPATA21 RNA expression shows 12,619 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where SPATA21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPATA21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPATA21 survival associations across molecular data types. SPATA21 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPATA21 RNA expression–survival associations across cancer types. High SPATA21 expression shows unfavorable associations in KIRC, ACC and MESO, but favorable associations in LUAD, READ and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SPATA21 RNA expression.
This table summarizes SPATA21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SPATA21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPATA21 shows lower tumor expression in BRCA and higher tumor expression in KIRC, LIHC, COAD, HNSC and BLCA. The KIRC box plot shows higher SPATA21 RNA expression in tumor versus normal tissue (log2 FC = +0.053, t-test p < 0.001).
This table shows molecular features associated with SPATA21 in patient tissues and cancer cell lines. In patient samples, SPATA21 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SPATA21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
